NCT04843098
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Phase changed: Phase 1/2 → Phase 1 Show 4 more changesShow less
- Eligibility criteria expanded, about 23 words
- Trial completed
- Final enrollment: 13 participants (planned 108)
- Study completion date changed from estimate of Jun 2025 to Apr 23, 2025
Notable Primary completion date changed from estimate of Jan 2024 to Nov 20, 2024v2 Show 4 more changesShow less
- Trial status: Not Yet Recruiting to Active, Not Recruiting
- Study sites: 0 to 1
- Study completion date: Jan 2024 to Jun 2025
- Start date changed from estimate of Apr 2021 to May 26, 2021
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Phase Ia -Dose Limiting Toxicity (DLT) of TL117 treatment
Timeframe: From time of the first dosing to time of Cycle 1 Day 28(each cycle is 28 days)
Phase Ib -Dose Limiting Toxicity (DLT) of TL117 plus paclitaxel combination treatment
Timeframe: From time of the first dosing to time of Cycle 1 Day 28(each cycle is 28 days)
Phase II - Objective response rate (ORR)
Timeframe: Every 8 weeks from date of first treatment until date of last treatment up to 12 months
Arms and interventions
Single arm, open labelExperimental
Phase 1a: All subjects receiving TL117 alone (20-120 mg); Phase 1b: All subjects receiving TL117 (MTD-1 or MTD) plus Paclitaxel; Phase 2: All subjects receiving TL117 in combination with Paclitaxel at RP2D
Drugs: TL117, Paclitaxel
Sites
1 site in 1 country
- Shanghai East HospitalShanghai, Shanghai Municipality, China